PMID: 7544030Aug 1, 1995Paper

Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer

Seminars in Oncology
G GiacconeH M Pinedo

Abstract

A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on the toxicity and pharmacokinetics of both agents was also assessed. To develop an ambulatory regimen for palliation of advanced NSCLC, paclitaxel was infused over 3 hours with standard premedication and carboplatin over 30 minutes. Cycles were repeated every 4 weeks. At each dose level, at least six patients were randomized to receive either paclitaxel followed by carboplatin or the reverse sequence. In the second and following cycles the alternate sequence was administered. The pharmacokinetics of both paclitaxel and carboplatin were compared in the first two cycles in at least two patients per dose level. Sixty-two patients have been entered in this study. Paclitaxel was increased from 100 mg/m2 in 25 mg/m2 increments up to a maximum of 225 mg/m2 combined with a fixed carboplatin dose (300 mg/m2). Thereafter, the drug doses were increased to a maximum of 400 mg/m2 carboplatin and 250 mg/m2 paclitaxel. In 243 cycles, the most frequen...Continue Reading

Citations

May 15, 1998·Current Problems in Cancer·C J Sweeney, A B Sandler
Aug 30, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·D Ferrigno, G Buccheri
Dec 22, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·S LaohavinijV Ratanatharathorn
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E LaackD K Hossfeld
Jun 27, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M E R O'BrienUNKNOWN EORTC Lung Cancer Group
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G FountzilasD Skarlos
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christiane D ThieneltKaren Kelly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
V R Bulusu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D H JohnsonR F De Vore
© 2021 Meta ULC. All rights reserved